The Evolution of LifeArc, a Translational Organisation

Netval 16th September 2019

Pauline Stasiak PhD
Investment Principal, Seed Fund
ACADEMIC AND NON PROFIT Institutions

Established 2000

MRC heritage

180+ employees

Not for Profit

>£37m R&D Spend

PHARMACEUTICAL BIOTECHNOLOGY Markets

4 drugs marketed

Technology Transfer

Drug Discovery

Funds

Diagnostics Development

Drug Discovery
Technology Transfer

- 7 Business Managers: identification, protection and commercialisation of IP for the MRC and LSHTM

- MRC Portfolio:
  - 563 IP assets of which 26% are patented
  - 67% of the patent portfolio is partnered; Of the remainder, 55% are being actively marketed and 25% have attracted interest from commercial partners
  - £22.3m gross income from commercialisation activities

- MRC 2018-19:
  - 55 new invention disclosures
  - 9 patent filings
  - 23 new licenses
Supporting Charities: Research to Patient

Portfolio Review
• Identifying, and where feasible, support research outcomes with the potential to deliver patient impact
• Ensuring funded research is protected & progressed for patient benefit

Advisory Service
• Ts & Cs review
• Update application and reporting forms to capture translational activities
• Revenue sharing guidelines
• Setting up collaborations
• Industry Engagement
• Drug discovery expertise in-house
• Therapeutic due diligence
• Marketing and IP advice
LifeArc-AUTM Technology Transfer Career Training Fellowships

Aim: to ease entry into the TT profession by providing TT training and practical experience

Who is it for? Life Scientist- Europe based

What it provides:

- 12 months technology transfer training program
- Attendance at local and international technology transfer conferences
- Mentor and career support
- Assistance to secure practical experience through an internship (optional)

All 2017-18 candidates secured a permanent TT position by the end of the fellowship

2019-2019 applicants include 5 UK based fellows and 2 EU fellows

Applications for 2019-20 LifeArc-AUTM fellows closed in July

Contact Anji.Miller@lifearc.org for more information; (www.lifearc.org/careers/fellowships)
The Centre for Therapeutics Discovery

Bridging the gap between basic research and early drug discovery

Working with industry, charities and universities

A purpose built LifeArc facility opened April 2016

> 90 scientists

State-of-the-art equipment and capabilities

Biology, Chemistry and Biotherapeutics teams in one place offers unique flexibility

Focus on, and collaborations in;
- neuroscience
- antimicrobials
- oncology
The Centre for Diagnostics Development

- Relocation to a purpose built facility 2017
- A team with significant industry experience in molecular diagnostics
- A regulatory compliant system
- Translate early stage diagnostic opportunities working collaboratively with academics, clinicians & industry partners to realise opportunities, build effective diagnostic tools & bring patient benefit
LifeArc Success in Numbers

70 antibodies humanised over the last 30 years

• Mouse, rat, rabbit, hamster, llama, nanobodies

20 entered in clinical trials

• To our knowledge, none failed for immunogenicity or reasons related to antibody properties

6 antibodies currently in clinical trials

4 humanised antibodies currently on the market

• Tysabri, Actemra, Entyvio and Keytruda
We are Self-Funded from Revenues

CD / UC

RA

MS

Cancer
LifeArc supports the development of novel therapeutics through its Funds:

• **Seed Fund**
  - £25 million to invest, over the next four years, in early stage UK therapeutics companies that focus on diseases with high unmet need
  - Any financial return will be re-invested to ensure that the fund is sustainable

• **Philanthropic Fund**
  - Awards grants, either directly to academics or together with rare disease charity partners
  - Qualifying projects must show a strong scientific rationale along with a credible development path
  - LifeArc will not ask for any financial return or intellectual property (IP) rights
Seed Fund Mission Statement

• The LifeArc Seed Fund is an early stage investor in biomedical start-ups, working with the wider LifeArc community and focussed on addressing the funding shortage between innovative science and venture investment in order to better deliver clinical benefit to the patient

• A venture facing, and therefore market and demand-driven fund, thereby fulfilling LifeArc’s mission of deliverability to the patient
Strategic Context

- There is a shortage (rather than gap) in the UK funding environment for intelligent institutional capital to bridge from innovative science to venture investment and beyond to the patient.
- LifeArc is financially equipped to help ameliorate this funding shortage and open up a new front to fulfil its mission of bringing innovative new medicines and diagnostics to the patient.
- LifeArc is well positioned to lever its existing capabilities in this activity – deal sourcing, value-adding services, existing relationships, to provide a real USP in the seed space.
- The “Philanthropic Fund:Seed Fund:Venture Fund” is a powerful axis addressing market needs for joined up financing from first investment to exit.
Seed Fund Strategy – Basic Parameters

- **Scope:** therapeutics (possibly also compelling diagnostics)

- **Focus:** will include but not be limited to; immune oncology, neurodegeneration, respiratory, AMR, metabolic and anti-inflammatory

- **Business model:** focussing on innovation and credible path to approval and patient use

- **Geography:** UK

- **Portfolio size:** 10 – 12. Invested over a four year period

- **Investment size:** up to £2.5m total per investee

- **Early VC endorsement** (a proxy for market “pull”)
Typical Attributes of a Potential Investee

• **Strong IP position**
• **Reputable scientists and institution**
• **Clinical validation of potential deliverables**
• **Demonstrable market pull – via VC, and/or industry/key adopters**
• **Good quality co-investors (if required)**
• **An existing company with a business plan**
• **A commercial champion engaged**
Thank you!

Dr Pauline Stasiak
pauline.stasiak@lifearc.org
www.lifearc.org